Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent
Authors:
Open Access
- 2 November 2019
- journal article
- review article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 8 (4) , 483-497
Abstract
Hepatitis A, an acute inflammatory liver disease caused by hepatitis A virus (HAV) infection from close contact with infected people, is highly endemic in the Indian subcontinent. Due to poor sanitary conditions, most of the population is exposed to the virus in childhood. At this age, the disease is asymptomatic and provides life-long protection against the disease. Due to rapid socioeconomic development in some areas, however, pockets of the population are reaching adolescence/adulthood without prior exposure to the virus and are thus susceptible to infection. At these ages, infection carries a higher risk of symptomatic disease and complications including mortality. This review of epidemiology and burden of disease studies in the Indian subcontinent, published since 2005, shows increasing evidence of a shift from high to intermediate endemicity in high-income—typically urban—populations. The prevalence of anti-HAV antibodies (previously reported at > 90%) is lower now in adolescents and young adults (e.g., around 80% in Bangladesh and 55% in 5–15 years in India). As a result, HAV is responsible for more acute viral hepatitis predominantly in this age group (e.g., > 15 years: 3.4% in 1999 to 12.3% in 2003 or high socioeconomic status 13–20 years: 27% in 1999 to 62% in 2003), with a greater clinical and economic burden. Numerous outbreaks due to HAV have been reported [e.g., Sri Lanka (2009–2010): > 13,000 affected; Kashmir (2015–2017): 12 outbreaks; Kerala (2012–2016): 84 outbreaks] from water or food contamination. Due to current shifts in endemicity, a growing proportion of the population is no longer exposed in childhood. As the disease remains highly endemic, it also provides a source for more severe disease in susceptible people at an older age and for outbreaks. Well-tolerated and effective vaccines are available and help prevent disease burden and provide long-term protection. These should now be used more widely to protect more patients from the growing disease burden of hepatitis A. Funding GlaxoSmithKline Biologicals SA. Plain Language Summary Plain language summary available for this article—please see Fig. 1 and the following link: https://doi.org/10.6084/m9.figshare.9963044. Plain Language Summary. Highlights the context of the article, the endemicity shift and the burden of hepatitis A in adolescents and adults and steps to be taken to address the impact of this diseaseKeywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 51 references indexed in Scilit:
- Massive hepatitis A outbreak in Sri Lanka in 2009: an indication of increasing susceptibility and epidemiological shift?Sri Lankan Journal of Infectious Diseases, 2013
- Hepatitis A: Epidemiology and prevention in developing countriesWorld Journal of Hepatology, 2012
- Community-based cross-sectional seroprevalence study of hepatitis A in BangladeshWorld Journal of Gastroenterology, 2009
- Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large InequalitiesPLOS Medicine, 2008
- Seroepidemiology of hepatitis A in voluntary blood donors from Pune, western India (2002 and 2004–2005)Epidemiology and Infection, 2007
- Increasing trend of acute hepatitis A in north India: Need for identification of high‐risk population for vaccinationJournal of Gastroenterology and Hepatology, 2006
- Hepatitis A Virus: From Discovery to VaccinesHepatology, 2006
- Cell mediated and antibody immune response to inactivated hepatitis A vaccineVaccine, 2005
- Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccinesVaccine, 2004
- Clinical manifestations and diagnosis of hepatitis A virus infectionVaccine, 1992